Literature DB >> 20554840

Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis.

Benjamin D Auerbach1, Mark F Bear.   

Abstract

Fragile X Syndrome (FXS), the most common inherited form of intellectual disability, is caused by loss of the fragile X mental retardation protein (FMRP). FMRP is a negative regulator of local mRNA translation downstream of group 1 metabotropic glutamate receptor (Gp1 mGluR) activation. In the absence of FMRP there is excessive mGluR-dependent protein synthesis, resulting in exaggerated mGluR-dependent long-term synaptic depression (LTD) in area CA1 of the hippocampus. Understanding disease pathophysiology is critical for development of therapies for FXS and the question arises of whether it is more appropriate to target excessive LTD or excessive mGluR-dependent protein synthesis. Priming of long-term potentiation (LTP) is a qualitatively different functional consequence of Gp1 mGluR-stimulated protein synthesis at the same population of CA1 synapses where LTD can be induced. Therefore we determined if LTP priming, like LTD, is also disrupted in the Fmr1 knockout (KO) mouse. We found that mGluR-dependent priming of LTP is of comparable magnitude in wild-type (WT) and Fmr1 KO mice. However, whereas LTP priming requires acute stimulation of protein synthesis in WT mice, it is no longer protein synthesis dependent in the Fmr1 KO. These experiments show that the dysregulation of mGluR-mediated protein synthesis seen in Fmr1 KO mice has multiple consequences on synaptic plasticity, even within the same population of synapses. Furthermore, it suggests that there is a bifurcation in the Gp1 mGluR signaling pathway, with one arm triggering synaptic modifications such as LTP priming and LTD and the other stimulating protein synthesis that is permissive for these modifications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554840      PMCID: PMC2934918          DOI: 10.1152/jn.00449.2010

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  44 in total

1.  Internalization of ionotropic glutamate receptors in response to mGluR activation.

Authors:  E M Snyder; B D Philpot; K M Huber; X Dong; J R Fallon; M F Bear
Journal:  Nat Neurosci       Date:  2001-11       Impact factor: 24.884

2.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1.

Authors:  K M Huber; J C Roder; M F Bear
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

3.  Evidence that fragile X mental retardation protein is a negative regulator of translation.

Authors:  B Laggerbauer; D Ostareck; E M Keidel; A Ostareck-Lederer; U Fischer
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

4.  Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.

Authors:  V Brown; P Jin; S Ceman; J C Darnell; W T O'Donnell; S A Tenenbaum; X Jin; Y Feng; K D Wilkinson; J D Keene; R B Darnell; S T Warren
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

5.  Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation.

Authors:  C R Raymond; V L Thompson; W P Tate; W C Abraham
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

6.  Altered synaptic plasticity in a mouse model of fragile X mental retardation.

Authors:  Kimberly M Huber; Sean M Gallagher; Stephen T Warren; Mark F Bear
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Long-lasting increase in cellular excitability associated with the priming of LTP induction in rat hippocampus.

Authors:  A S Cohen; C M Coussens; C R Raymond; W C Abraham
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

8.  The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95.

Authors:  Peter K Todd; Kenneth J Mack; James S Malter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

Review 9.  The mGluR theory of fragile X mental retardation.

Authors:  Mark F Bear; Kimberly M Huber; Stephen T Warren
Journal:  Trends Neurosci       Date:  2004-07       Impact factor: 13.837

10.  The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses.

Authors:  Francesca Zalfa; Marcello Giorgi; Beatrice Primerano; Annamaria Moro; Alessandra Di Penta; Surya Reis; Ben Oostra; Claudia Bagni
Journal:  Cell       Date:  2003-02-07       Impact factor: 41.582

View more
  33 in total

Review 1.  Toward fulfilling the promise of molecular medicine in fragile X syndrome.

Authors:  Dilja D Krueger; Mark F Bear
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

2.  Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling.

Authors:  Ravi S Muddashetty; Vijayalaxmi C Nalavadi; Christina Gross; Xiaodi Yao; Lei Xing; Oskar Laur; Stephen T Warren; Gary J Bassell
Journal:  Mol Cell       Date:  2011-06-10       Impact factor: 17.970

3.  Reduced excitatory amino acid transporter 1 and metabotropic glutamate receptor 5 expression in the cerebellum of fragile X mental retardation gene 1 premutation carriers with fragile X-associated tremor/ataxia syndrome.

Authors:  Dalyir I Pretto; Madhur Kumar; Zhengyu Cao; Christopher L Cunningham; Blythe Durbin-Johnson; Lihong Qi; Robert Berman; Stephen C Noctor; Randi J Hagerman; Isaac N Pessah; Flora Tassone
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

4.  A presynaptic role for FMRP during protein synthesis-dependent long-term plasticity in Aplysia.

Authors:  Sally M Till; Hsiu-Ling Li; Maria Concetta Miniaci; Eric R Kandel; Yun-Beom Choi
Journal:  Learn Mem       Date:  2010-12-21       Impact factor: 2.460

Review 5.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 6.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 7.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

8.  Pharmacological rescue of cortical synaptic and network potentiation in a mouse model for fragile X syndrome.

Authors:  Tao Chen; Jing-Shan Lu; Qian Song; Ming-Gang Liu; Kohei Koga; Giannina Descalzi; Yun-Qing Li; Min Zhuo
Journal:  Neuropsychopharmacology       Date:  2014-02-20       Impact factor: 7.853

9.  Reduced activity-dependent protein levels in a mouse model of the fragile X premutation.

Authors:  Ramona E von Leden; Lindsey C Curley; Gian D Greenberg; Michael R Hunsaker; Rob Willemsen; Robert F Berman
Journal:  Neurobiol Learn Mem       Date:  2014-01-23       Impact factor: 2.877

10.  Impaired cognitive discrimination and discoordination of coupled theta-gamma oscillations in Fmr1 knockout mice.

Authors:  Basma Radwan; Dino Dvorak; André A Fenton
Journal:  Neurobiol Dis       Date:  2016-01-12       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.